NASD
| Health Care |
Pharmaceuticals
Acurx Pharmaceuticals Inc. (ACXP)
LAST (31 Mar)
MARKET CAP
VOLUME
| Open | 0.41 |
| Previous Close | 0.4084 |
| Day Range | 0.38 - 0.41 |
| 52-Week Range | 0.38 - 3.33 |
| All-Time High | 8.82 |
| Avg. Volume (50-day) | 289,140.47 |
| EPS (TTM) | -0.8792 |
| Next Earnings Date | 2025-05-15 (BMO) |
| Last Earnings Date | 2025-03-18 |
| Forward Annual Dividend (Yield) | - |
| Trailing Annual Dividend (Yield) | - |
| Options | Yes |
| P/E Ratio | -0.4600 |
| PEG Ratio | - |
| Price to Book | 11.31 |
| Price to Cash Flow | - |
| Price to Free Cash Flow | - |
| Total Sales (TTM) | - |
| Revenue per Share (TTM) | - |
| Shares Outstanding | 22.043 M |
| Share Float (%) | 19.14 M |
| % Held by Institutions | 6.51 |
| Dividends Per Share (TTM) | - |
| Ex-Dividend Date | - |
| +/- EMA(20) | 0.48 (-18.75%) |
| +/- SMA(50) | 0.65 (-40.00%) |
| +/- SMA(200) | 1.5 (-74.00%) |
| 5-Day Perf. | -9.49% |
| 1-Month Perf. | -45.03% |
| 3-Month Perf. | -52.09% |
| 6-Month Perf. | -79.47% |
| YTD Perf. | -52.09% |
| 1-Year Perf. | -84.08% |
| RSI(14) | 29.11 |
| ATR(14) | 0.04 |
| ADX(14) | 33.42 |
| Beta (5Y) | - |
FOR STOCKCHARTS MEMBERS ONLY
Unlock earnings and revenue history when you join StockCharts
As a StockCharts Member, you can review earnings results and analyze revenue and earnings growth over time. Bring a balance of technicals and fundamentals to your approach when you join today!
ACXP
Acurx Pharmaceuticals Inc.
Sector: Health Care
Industry: Pharmaceuticals
Employees: 4
Description
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.
ACXP has triggered the following predefined scans:
| P&F Double Bottom Breakdown |
| Moved Below Lower Price Channel |
| Elder Bar Turned Red |
| New 52-week Lows |
FOR STOCKCHARTS MEMBERS ONLY
Unlock custom technical alerts when you join StockCharts
As a StockCharts Member, you can create your own unique alerts with the technical criteria that matters most to you. Stay ahead of important moves and never miss a thing in the markets.
FOR STOCKCHARTS MEMBERS ONLY
Unlock ChartLists to save and organize your charts when you join StockCharts
As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere.
